Open AccessDevelopment of a physiologically based pharmacokinetic model for intravenous lenalidomide in mice
Author(s) -
Jim H. Hughes,
Richard N. Upton,
Stephanie E Reuter,
Darlene M. Rozewski,
Mitch A. Phelps,
David J. R. Foster
Publication year - 2019
Publication title -
cancer chemotherapy and pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.112
H-Index - 111
eISSN - 1432-0843
pISSN - 0344-5704
DOI - 10.1007/s00280-019-03941-z
Subject(s) - lenalidomide , pharmacokinetics , pharmacology , medicine , multiple myeloma
Lenalidomide is used widely in B-cell malignancies for its immunomodulatory activity. It is primarily eliminated via the kidneys, with a significant proportion of renal elimination attributed to active processes. Lenalidomide is a weak substrate of P-glycoprotein (P-gp), though it is unclear whether P-gp is solely responsible for lenalidomide transport. This study aimed to determine whether the current knowledge of lenalidomide was sufficient to describe the pharmacokinetics of lenalidomide in multiple tissues.